NCT02639182已完成2 期
A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 133
- 试验地点
- 26
- 主要终点
- Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigator Radiologic Review
研究概览
简要总结
The purpose of this study was to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic renal cell carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of RCC
- •Non-clear subjects must be ENPP3 positive, defined as IHC H-score ≥15
- •Has evidence of progression on or after the last regimen received:
- •Clear cell subject: must have received at least 2 prior systemic regimens, one of which is an anti-VEGF agent.
- •Non-clear cell subject: must have received at least one prior anti-VEGF regimen
- •Has measurable disease according to Response Criteria for Solid Tumors (RECIST v.1.1)
- •Has Eastern Cooperative Group (ECOG) performance status of 0 or 1
- •Has archive tumor tissue from primary tumor or metastatic site (excluding bone), for which the source and availability have been confirmed.
- •If no archive tissue is available, the subject may elect to have a biopsy performed to obtain tissue.
- •Has adequate organ function including:
- •Hematopoietic function as follows:
- •Absolute neutrophil count (ANC) ≥ 1.5 x 10 9/L
- •Platelet count ≥ 100 x 10 9/L
- •Hemoglobin ≥ 9 g/dL (transfusions are allowed)
- •Renal Function as follows:
- •Creatinine ≤ 1.5 x upper limit of normal (ULN), or calculated glomerular filtration rate (GFR) > 40 mL/min (Cockcroft-Gault) if creatinine > 1.5x ULN
- •Hepatic function, as follows:
- •Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN or ≤ 5x ULN if known liver metastases
- •Total bilirubin ≤ 1.5 x ULN
- •Prothrombin time (PT) and activated partial thromboplastin time (aPTT) levels ≤1.5 x ULN. If institution does not report PT value, the international normalization ratio (INR) must be ≤ ULN.
- •If subject is receiving Coumadin (warfarin), a stable international normalization ratio (INR) of 2-3 is required.
- •No clinical symptoms of hypothyroidism
- •Urine Protein to Creatinine Ratio (uPCR) < 2.0
- •If uPCR ≥ 2.0 then a 24-hour urine collection can be performed to qualify. If this is performed to qualify, the protein result must be < 2 g per 24 hours.
- •Female subject must either:
- •Be of non-childbearing potential:
- •post-menopausal (defined as at least 1 year without any menses) prior to Screening, or
- •documented surgically sterile
- •Or, if of childbearing potential,
- •Agree not to try to become pregnant during the study and for 6 months after the final study drug administration
- •And have a negative serum pregnancy test ≤ 10 days of cycle 1, day 1 (C1D1)
- •And, if heterosexually active, agree to consistently use 2 forms of highly effective birth control* (at least one of which must be a barrier method) starting at Screening and throughout the study period and for 6 months after the final study drug administration.
- •Female subject must agree not to breastfeed starting at Screening and throughout the study period, and for 6 months after the final study drug administration.
- •Female subject must not donate ova starting at Screening and throughout the study period, and for 6 months after the final study drug administration.
- •Male subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception* consisting of 2 forms of birth control (at least one of which must be a barrier method) starting at Screening and continue throughout the study period, and for 6 months after the final study drug administration
- •Male subject must not donate sperm starting at Screening and throughout the study period and, for 6 months after the final study drug administration
- •Note: *Highly effective forms of birth control include:
- •Consistent and correct usage of established oral contraception.
- •Established intrauterine device (IUD) or intrauterine system (IUS).
- •Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
排除标准
- •Has previously been treated with axitinib, AGS-16C3F, or AGS-16M8F
- •Has untreated brain metastasis. In the case of a solitary brain metastasis which has been resected, there must be evidence of a disease-free interval of at least 3 months post-surgery. For brain metastases treated with whole brain or stereotactic radiation therapy, brain imaging must be stable > 3 months. All subjects previously treated for brain metastases must be stable off corticosteroid therapy for at least 28 days prior to C1D
- •Has uncontrolled hypertension defined as blood pressure > 150/90 on medication(s) by 2 blood pressure readings taken at least 1 hour apart.
- •Has gastrointestinal abnormalities including:
- •inability to take oral medication;
- •requirement for intravenous alimentation;
- •prior surgical procedures affecting absorption including total gastric resection;
- •active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy;
- •malabsorption syndromes such as celiac disease, cystic fibrosis, inflammatory bowel disease, systemic sclerosis, and carcinoid syndrome
- •Has ocular conditions such as:
- •Active infection or corneal ulcer
- •Monocularity
- •Visual acuity of 20/70 or worse in both eyes
- •History of corneal transplantation
- •Contact lens dependent (if using contact lens, must be able to switch to glasses during the entire study duration)
- •Uncontrolled glaucoma (topical medications allowed)
- •Uncontrolled or active ocular problems (e.g., retinopathy, macular edema, active uveitis, wet macular degeneration) requiring surgery, laser treatment, or intravitreal injections
- •Papilledema or other active optic nerve disorder
- •Has used any investigational drug (including marketed drugs not approved for this indication) ≤ 14 days of C1D
- •No time limit applies to the use of marketed drugs approved for this indication provided that the subject has progressed on the treatment and all toxicities attributable to the drug have resolved, returned to baseline or stabilized.
- •Has known sensitivity to any of the ingredients of:
- •investigational product AGS-16C3F and/or,
- •Inlyta® (axitinib) and/or,
- •1% prednisolone acetate ophthalmic suspension and any other corticosteroids.
- •Is currently using (i.e., within 14-days prior to first dose) drugs that are known strong CYP3A4/5 inhibitors / inducers.
- •Thromboembolic event (e.g., deep vein thrombosis [DVT] and pulmonary embolism [PE]) ≤ 4 weeks of C1D
- •Subjects who had a thromboembolic event ≤ 4 weeks of C1D1 must be receiving adequate anticoagulation treatment for at least 2 weeks before C1D1 and must continue as clinically indicated post first dose
- •Has history bleeding disorders (e.g., pulmonary hemorrhage, significant hemoptysis, menometrorrhagia not responding to hormonal treatment) ≤ 2 months before C1D1
- •Has active angina or Class III or IV Congestive Heart Failure (New York Heart Association CHF Functional Classification System) or clinically significant cardiac disease within 6 months of randomization, including myocardial infarction, unstable angina, Grade 2 or greater peripheral vascular disease, congestive heart failure, or arrhythmias not controlled by medication.
- •Had major surgery ≤ 4 weeks of C1D1
- •Is pregnant (confirmed by positive serum pregnancy test) or lactating
- •Has active infection requiring treatment with systemic (intravenous or oral) anti-infectives (antibiotic, antifungal, or antiviral agent) ≤ 10 days of C1D1
- •Is unwilling or unable to comply with study requirements
- •Has any medical or psychiatric disorder that compromises the ability of the subject to give written informed consent, and/or comply with the study procedures.
研究组 & 干预措施
AGS-16C3F
Experimental
Participants received 1.8 milligram per kilogram (mg/kg) of AGS-16C3F once every three weeks by single intravenous (IV) infusion.
干预措施: AGS-16C3F (Drug)
Axitinib
Active Comparator
Participants received 2 to 10 milligram (mg) of axitinib twice daily by oral administration as defined in the product label and per local institutional guidelines.
干预措施: Axitinib (Drug)
结局指标
主要结局
Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Investigator Radiologic Review
时间窗: From date of randomization to the earliest of either documented disease progression or death from any cause (up to 53 months)
PFS was defined as the time from the date of randomization to the earliest of documented disease progression as defined by RECIST v.1.1 or death from any cause. PFS was analysed using Kaplan-Meier estimates. Progressive disease (PD) was defined as at least a 20% increase in the sum of diameters (longest for non-nodal lesions, short axis for nodal lesions) of the target lesions taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of 1 or more new lesions is also considered progression. Participants were censored if there were 2 or more than 2 consecutive missing assesments immediately prior to death or progression; or no death and no postebaseline assesments; or if ininitiated non protocol anticancer treatment prior to death or prior to documentation of disease progression; or alive and not progressed.
次要结局
- Duration of Response (DOR) Based on the Investigator's Radiographic Assessment(From date of first objective response until data cutoff date of 21 August 2019 (up to 40 months))
- Overall Survival (OS)(Date of randomization until the date of death from any cause (up to 53 months))
- Number of Participants With Adverse Events(From first dose up to 53 months)
- Mean Predose Serum Concentration (Ctrough) of ADC(Predose on cycle 2, 3, 4, 6, 14, and 18 (each cycle is 21 days))
- Objective Response Rate (ORR) Based on the Investigator's Radiographic Assessment(From date of randomization until data cutoff date of 21 August 2019 (up to 40 months))
- Terminal Elimination Half-life (t1/2) of Cys-mcMMAF(Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days))
- PFS Per RECIST v1.1 as Assessed by Blinded Central Radiology Assessment(From date of randomization to the earliest of either documented disease progression or death from any cause (up to 40 months))
- Maximum Observed Serum Concentration (Cmax) of Antibody Drug Conjugate (ADC)(Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days))
- Time to Maximum Observed Serum Concentration (Tmax) of ADC(Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days))
- Maximum Serum Concentration (Cmax) of Total Antibody (TAb)(Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days))
- Time to Maximum Observed Serum Concentration (Tmax) of Tab(Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days))
- Disease Control Rate (DCR) Based on the Investigator's Radiographic Assessment(Date of randomization until data cutoff date of 21 August 2019 (up to 40 months))
- Maximum Serum Concentration (Cmax) of Cysteine Adduct of Maleimidocaproyl Monomethyl Auristatin F (Cys-mcMMAF)(Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days))
- Area Under the Concentration Versus Time Curve From Time Zero to 21days (AUC0 to 21) of ADC(Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days))
- Terminal Elimination Half-life (t1/2) of ADC(Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days))
- Mean Predose Serum Concnetration (Ctrough) of TAb(Predose on cycle 2, 3, 4, 6, 14, and 18 (each cycle is 21 days))
- Area Under the Concentration Versus Time Curve From Time Zero to 21days (AUC0 to 21) of TAb(Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days))
- Terminal Elimination Half-life (t1/2) of Tab(Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days))
- Mean Predose Serum Concnetration (Ctrough) of Cys-mcMMAF(Predose on cycle 2, 3, 4, 6, 14, and 18 (each cycle is 21 days))
- Time to Maximum Observed Serum Concentration (Tmax) of Cys-mcMMAF(Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days))
- Area Under the Concentration Versus Time Curve From Time Zero to 21days (AUC0 to 21) of Cys-mcMMAF(Predose, end of infusion, 4, 24, 72, 336 hours postdose of cycle 1 and cycle 4 (each cycle is 21 days))
研究者
研究点 (26)
Loading locations...
相似试验
已完成
2 期
A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive TherapyMetastatic Colorectal CancerNCT02743221Institut de Recherches Internationales Servier154
已完成
2 期
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerRecurrent Ovarian CancerRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal CarcinomaNCT03776812Corcept Therapeutics178
已完成
2 期
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) TumorsRectal CancerMetastatic Colorectal CancerColorectal CancerColon CancerNCT00819780Amgen285
已完成
2 期
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line TherapyColorectal CancerNCT01478594AVEO Pharmaceuticals, Inc.265
已完成
2 期
Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With BevacizumabColorectal CancerNCT01442649UNICANCER133